Astrotech Corporation revenue by segment ASTC

Annual Quarterly

Astrotech Corporation splits its revenue into 4 lines in its filings. The largest line in Q4 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $610,000, 67% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	Q4 FY2026 Jun 30, 2026	Q3 FY2026 Mar 31, 2026	Q4 FY2025 Jun 30, 2025	Q3 FY2025 Mar 31, 2025	Q2 FY2025 Dec 31, 2024	Q1 FY2025 Sep 30, 2024	Q4 FY2024 Jun 30, 2024	Q3 FY2024 Mar 31, 2024
Revenue	1	0	1	1	0	0	0	0
Product	1 -24.1% share 66.8%	0 -57.8% share 42.9%	1 share 76.6%	0 share 65.2%	0 share 74.7%	—	—	—
Grant	0 +78.3% share 22.5%	-0 -160.3% share -12.0%	0 share 11.0%	0 share 12.7%	0 share 9.6%	—	—	—
Services	0 -25.4% share 10.6%	0 +287.5% share 63.3%	0 share 12.4%	0 share 10.5%	0 share 7.3%	0 share 26.5%	—	—
Warranty	—	0 -67.7% share 5.8%	—	0 share 11.6%	0 share 8.4%	0 share 73.5%	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Laboratory Analytical Instruments (SIC 3826)
Listed as: ASTC (Nasdaq)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: Austin, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1001907
Former names: ASTROTECH Corp \WA\ (until Aug 24, 2015); SPACEHAB INC \WA\ (until Feb 25, 2009)

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.